13,335 Shares in Inari Medical, Inc. (NASDAQ:NARI) Bought by Legato Capital Management LLC

Legato Capital Management LLC purchased a new position in Inari Medical, Inc. (NASDAQ:NARI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 13,335 shares of the company’s stock, valued at approximately $681,000.

A number of other hedge funds also recently modified their holdings of the stock. Jennison Associates LLC increased its position in shares of Inari Medical by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after purchasing an additional 186,617 shares during the period. R Squared Ltd bought a new position in shares of Inari Medical in the fourth quarter worth $45,000. KBC Group NV increased its position in shares of Inari Medical by 31.5% in the fourth quarter. KBC Group NV now owns 2,333 shares of the company’s stock worth $119,000 after purchasing an additional 559 shares during the period. AMI Asset Management Corp bought a new position in shares of Inari Medical in the fourth quarter worth $1,651,000. Finally, GAMMA Investing LLC grew its position in Inari Medical by 66.8% in the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock valued at $100,000 after acquiring an additional 786 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

Inari Medical Trading Up 0.0 %

Shares of NARI stock opened at $79.93 on Friday. The business’s 50-day moving average price is $67.92 and its 200-day moving average price is $53.94. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $79.95. The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of -59.21 and a beta of 1.02.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Canaccord Genuity Group reiterated a “hold” rating and issued a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Truist Financial lifted their target price on Inari Medical from $50.00 to $63.00 and gave the company a “hold” rating in a research report on Wednesday, December 18th. William Blair reiterated a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Baird R W cut Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $68.00.

Insider Activity

In related news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the transaction, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at $24,289,449.90. The trade was a 0.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the completion of the transaction, the director now directly owns 238,987 shares in the company, valued at approximately $14,451,543.89. This represents a 45.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 323,000 shares of company stock valued at $18,669,070. 10.60% of the stock is currently owned by corporate insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.